XBIvsIBBETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) belong to the same industry segment: US Health Care. XBI's top 2 sector exposures are Healthcare and Finance. In contrast, IBB's top sector exposures are Healthcare, Non-Corporate and Non-Energy Materials. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.44% for IBB. XBI is up 28.61% year-to-date (YTD) with +$337M in YTD flows. IBB performs worse with 21.43% YTD performance, and +$382M in YTD flows. Run a side-by-side ETF comparison of XBI and IBB below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs IBB performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/18/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI IBB | -2.07%+0.61% | +11.46%+17.87% | +28.61%+21.43% | +62.85%+42.82% | +107.67%+64.91% | +22.69%+22.20% |
| Flows | XBI IBB | -$260M+$239M | +$638M+$828M | +$337M+$382M | +$1.16B+$1.81B | -$662M-$564M | +$1.77B-$1.12B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI IBB | +29.38%+24.62% | +27.95%+21.79% | +28.31%+21.11% | +32.90%+22.48% |
| Max drawdown | XBI IBB | -10.46%-6.84% | -10.46%-9.61% | -32.94%-24.82% | -53.28%-38.96% |
| Max drawdown duration | XBI IBB | 40d30d | 40d151d | 331d377d | 1622d1523d |
Trading data
XBI | IBB | |
Last sale 9/21/2026 at 1:30 PM | $158.23 | $207.16 |
| Previous close 09/18/2026 | $156.72 | $204.56 |
| Consolidated volume 09/18/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | IBB | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/21/2026 at 1:30 PM
Live
Closed
XBI | IBB | |
|---|---|---|
| Last price | $158.23 | $207.16 |
| 1D performance | +0.96% | +1.27% |
| AuM | $10.34 B | $10.45 B |
| E/R | 0.35% | 0.44% |
Characteristics
XBI | IBB | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | iShares |
| Benchmark | S&P Biotechnology Select Industry Index | ICE Biotechnology Index |
| N° of holdings | 149 | 240 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | February 5, 2001 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.3%
Other
4.7%
IBB
USA
86.04%
Other
13.96%
Sectors
XBI
Healthcare
99.41%
Other
0.59%
IBB
Healthcare
99.83%
Other
0.17%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
20.29%
IBB
Total weight of top 15 holdings out of 15
54.48%
Top 15 holdings
Data as of July 31, 2026
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
IBB
Amgen, Inc.
8.42%
Vertex Pharmaceuticals, Inc.
7.87%
Gilead Sciences, Inc.
7.14%
Regeneron Pharmaceuticals, Inc.
5.84%
argenx SE
3.55%
Natera, Inc.
2.88%
Revolution Medicines, Inc.
2.87%
Illumina, Inc.
2.42%
Biogen, Inc.
2.38%
Alnylam Pharmaceuticals, Inc.
2.14%
BeOne Medicines Ltd.
2.01%
Incyte Corp.
1.91%
Insmed, Inc.
1.71%
United Therapeutics Corp.
1.69%
Moderna, Inc.
1.65%
Frequently asked questions about XBI and IBB
How have the XBI and IBB ETFs performed in 2026?
As of September 18, 2026, XBI is up 28.61% year-to-date (YTD), while IBB has returned 21.43%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or IBB?
Year-to-date, the XBI ETF saw +$337M in flows, compared to +$382M for IBB.
Which ETF is more volatile: XBI or IBB?
Over the past year, XBI had a volatility of 27.95%, while IBB experienced 21.79%.
Which ETF is bigger: XBI or IBB?
As of September 18, 2026, XBI holds $10.34 B in assets under management (AUM), while IBB manages $10.45 B.
What sectors do the XBI and IBB ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, IBB focuses on Healthcare.
What are the top holdings of the XBI ETF and IBB ETF?
XBI top holdings include Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc.. IBB holds in its top three: Amgen, Inc., Vertex Pharmaceuticals, Inc. and Gilead Sciences, Inc..
Which ETF is more diversified: XBI or IBB?
XBI holds 151 securities with 20.29% of its assets in the top 15. IBB has 241 securities and a top 15 weight of 54.48%.
Advertisement
Latest news about XBI & IBB
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
IBB
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
IBB
Investing in the Aging Population: A Look at Bonds and Pharma ETFs
March 27, 2023
IBB
Health is Wealth: A look at the Healthcare Sector
January 24, 2023
IBB
Advertisement
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
IBB
Advertisement
